We are live on ! Find out more
ACM

Altium Capital Management Portfolio holdings

AUM $42M
This Fund
S&P 500
This Quarter Est. Return
+8.33%
1 Year Est. Return
–
3 Year Est. Return
–
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$180M
AUM Growth
-$16.6M
Cap. Flow
-$8.49M
Cap. Flow %
-4.71%
Top 10 Hldgs %
42.71%
Holding
128
New
34
Increased
5
Reduced
15
Closed
37

Top Buys

Rank Stock Value
1
AVDL
Avadel Pharmaceuticals
AVDL
+$4.11M
2
PEN icon
Penumbra
PEN
+$4.08M
3
ATEC icon
Alphatec Holdings
ATEC
+$3.82M
4
INSP icon
Inspire Medical Systems
INSP
+$3.16M
5
VREX icon
Varex Imaging
VREX
+$3.14M

Top Sells

Rank Stock Value
1
AKRO
Akero Therapeutics
AKRO
+$6.85M
2
PEPL
PepperLime Health Acquisition Corporation Class A Ordinary Share
PEPL
+$6.47M
3
ITCI
Intra-Cellular Therapies Inc.
ITCI
+$5.29M
4
RYTM icon
Rhythm Pharmaceuticals
RYTM
+$4.95M
5
KRTX
Karuna Therapeutics, Inc. Common Stock
KRTX
+$4.32M

Sector Composition

Rank Sector Weight
1 Healthcare 85.22%
2 Financials 3.64%
3 Technology 0.85%
4 Communication Services 0.51%
5 Materials 0.17%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
REPL icon
26
Replimune Group
REPL
$1.03B
$2.61M 1.45%
148,000
-12,000
-8% -$285K
BBIO icon
27
BridgeBio Pharma
BBIO
$16.1B
$2.57M 1.43%
+155,000
New +$1.81M
MDXG icon
28
MiMedx Group
MDXG
$609M
$2.55M 1.42%
+748,000
New +$2.9M
NSTG
29
DELISTED
NanoString Technologies, Inc.
NSTG
$2.24M 1.24%
+225,992
New +$2.24M
VERA icon
30
Vera Therapeutics
VERA
$2.31B
$2.22M 1.23%
+286,000
New +$2.21M
ILMN icon
31
Illumina
ILMN
$28.7B
$2.09M 1.16%
+9,252
New +$1.89M
TGVC
32
DELISTED
TG Venture Acquisition Corp. Class A Common Stock
TGVC
$2.07M 1.15%
+200,000
New +$2.06M
PACB icon
33
Pacific Biosciences
PACB
$370M
$2.06M 1.14%
178,000
-187,000
-51% -$1.86M
BLRX
34
BioLineRX
BLRX
$12.1M
$2.02M 1.12%
56,991
-20,600
-27% -$542K
KPTI icon
35
Karyopharm Therapeutics
KPTI
$45.3M
$1.97M 1.09%
+33,719
New +$1.66M
CVRX icon
36
CVRx
CVRX
$66.3M
$1.91M 1.06%
+205,000
New +$2.71M
VTYX
37
DELISTED
Ventyx Biosciences
VTYX
$1.84M 1.02%
+55,000
New +$2.14M
DYN icon
38
Dyne Therapeutics
DYN
$4.72B
$1.79M 0.99%
+155,000
New +$2.01M
SILK
39
DELISTED
Silk Road Medical, Inc. Common Stock
SILK
$1.76M 0.98%
+45,000
New +$2.2M
WGS icon
40
GeneDx Holdings
WGS
$2.24B
$1.67M 0.93%
+139,030
New +$1.85M
PCVX icon
41
Vaxcyte
PCVX
$8.54B
$1.61M 0.89%
43,000
– –
CRNX icon
42
Crinetics Pharmaceuticals
CRNX
$8.9B
$1.61M 0.89%
+100,000
New +$1.85M
MRNS
43
DELISTED
Marinus Pharmaceuticals, Inc
MRNS
$1.58M 0.88%
+228,714
New +$1.43M
ADRT
44
DELISTED
Ault Disruptive Technologies Corporation
ADRT
$1.57M 0.87%
150,000
– –
CYCU
45
Cycurion Inc
CYCU
$6.86M
$1.02M 0.57%
+3,360
New +$1.03M
PEPL
46
DELISTED
PepperLime Health Acquisition Corporation Class A Ordinary Share
PEPL
$1.02M 0.57%
100,000
-635,000
-86% -$6.47M
THRX
47
DELISTED
Theseus Pharmaceuticals, Inc. Common Stock
THRX
$1M 0.56%
+112,614
New +$1.11M
HRMY icon
48
Harmony Biosciences
HRMY
$2.26B
$980K 0.54%
+30,000
New +$1.37M
FATBW
49
DELISTED
FAT Brands Inc. Warrant
FATBW
$897K 0.5%
227,000
– –
MITA
50
DELISTED
Coliseum Acquisition Corp. Class A Ordinary Share
MITA
$872K 0.48%
85,000
– –
1
2
3 4 5

Similar funds

TA
TLS Advisors Miami, Florida $42.1M AUM 25.99% 1-Year Est. Return
SIM
Spark Investment Management New York $41.6M AUM 80.97% 1-Year Est. Return
VEPM
Vista Equity Partners Management San Francisco, California $42.7M AUM 16.65% 1-Year Est. Return
BCM
Bratton Capital Management Fort Worth, Texas $40.7M AUM 43.1% 1-Year Est. Return
VAM
Vazirani Asset Management New York $43.4M AUM 84.05% 1-Year Est. Return
SCM
Stadium Capital Management New Canaan, Connecticut $40.6M AUM 5.83% 1-Year Est. Return
CAS
CTC Alternative Strategies Chicago, Illinois $44M AUM 43.15% 1-Year Est. Return
CF
Crosspoint Financial Tustin, California $39.8M AUM 14.13% 1-Year Est. Return

Altium Capital Management's Q1 2023 Portfolio in Review

As of Q1 2023, Altium Capital Management held 128 positions worth $180M, down 8.5% from $197M the previous quarter. Its ten largest holdings account for 43% of the portfolio.

Altium Capital Management withdrew a net $8.49M in Q1 2023, closing 37 positions and reducing 15 holdings. Its most notable exit was Akero Therapeutics, an estimated $6.85M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 85% of assets, down from 89% a quarter earlier, followed by Financials and Technology.

Against the trend, Altium Capital Management opened a new position in Avadel Pharmaceuticals worth $4.58M.

  • Altium Capital Management's largest Q1 2023 buy was Avadel Pharmaceuticals: 500,000 shares worth $4.58M.
  • Altium Capital Management added most to CTI BioPharma Corp. (DE) Common Stock in Q1 2023, an estimated $2.08M increase.
  • Altium Capital Management's biggest Q1 2023 reduction was PepperLime Health Acquisition Corporation Class A Ordinary Share, cutting an estimated $6.47M.
  • Altium Capital Management fully exited Akero Therapeutics in Q1 2023, selling an estimated $6.85M.
  • Altium Capital Management's ten largest holdings make up 43% of its $180M portfolio in Q1 2023.
  • Altium Capital Management opened 34 new positions and closed 37 in Q1 2023.
  • Altium Capital Management's portfolio value fell 8.5% quarter-over-quarter to $180M.

Based on Altium Capital Management's 13F filing for Q1 2023, filed 15 May 2023.